Skip to main content

Table 2 Longitudinal analysis of phase contrast flow measures in both MS patients and HCs

From: Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy

AoS-derived measuresHCs (n = 13)MS (n = 29)
BaselineFollow-upBL to FU
p-value
BaselineFollow-upBL to FU
p-value
Vmean systolic peak (cm/s)5.10 ± 2.314.89 ± 2.10.5795.46 ± 2.165.43 ± 1.730.939
Vmean diastolic peak (cm/s)3.75 ± 2.284.14 ± 2.370.2044.22 ± 1.324.06 ± 1.200.415
Vmax systolic peak (cm/s)9.16 ± 4.649.88 ± 5.030.1779.85 ± 3.569.54 ± 2.970.53
Vmax diastolic peak (cm/s)6.31 ± 3.197.61 ± 4.350.0357.23 ± 2.007.86 ± 2.760.037
Average area (mm2)2.62 ± 1.202.86 ± 1.260.193.12 ± 1.073.69 ± 1.550.001*
Flow rate systolic peak (ml/min)8.65 ± 6.058.78 ± 5.120.88210.36 ± 5.5312.16 ± 7.300.051
Flow rate diastolic peak (ml/min)6.57 ± 5.597.55 ± 5.720.2077.76 ± 3.519.33 ± 5.640.023
Net vol caudal (µl/beat)37.74 ± 25.3433.29 ± 19.410.33446.93 ± 27.3150.49 ± 34.40.391
Net vol cranial (µl/beat)37.89 ± 36.7538.92 ± 38.50.88541.13 ± 23.5645.86 ± 32.220.208
  1. HCs healthy controls, MS multiple sclerosis, AoS Aqueduct of Sylvius, Vmean average velocity, Vmax maximal velocity, BL baseline, FU follow-up
  2. All measures are shown as mean ± standard deviation. Paired repeated measure analysis was utilized. p-values lower than 0.05 were considered statistically significant and shown in bold italics where trending values are shown in italics
  3. * Statistically significant after false discovery rate correction